Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis
AssigneeGeorg-August-UniversitäT GöTtingen Stiftung öFfentlichen Rechts, UniversitäTsmedizin
InventorsPaul Lingor, Lars Tönges
Life of this patent
Estimating the term…
Abstract
The invention relates to a new use of a known Rho kinase inhibitor, fasudil or a fasudil derivative selected from hydroy-fasudil or dimethylfasudil, in the treatment of amyotrophic lateral sclerosis (ALS).
Claims21
1-43. (canceled)
A method of treating a subject suffering or prone to suffer from sporadic or familial ALS, wherein the method comprises administering a pharmaceutical composition, comprising or consisting of fasudil (1-(5-isoquinolinesulfonyl)homopiperazine), or a fasudil derivative selected from hydroxy-fasudil (1-(1-hydroxyl-5-isoquinolinesulfonyl)homopiperazine) and dimethyl-fasudil ((S)—H-2-Methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]-hexahydro-1H-1,4-diazepine), or a pharmaceutically acceptable salt thereof, to the subject.
A method of improving motor coordination in a subject suffering or prone to suffer from sporadic or familial ALS, wherein the method comprises administering a pharmaceutical composition, comprising or consisting of fasudil, or a fasudil derivative selected from hydroxy-fasudil and dimethyl-fasudil, or a pharmaceutically acceptable salt thereof, to the subject.
Dependencies are inferred from the claim text.